artesunic acid has been researched along with Cancer of Liver in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 7 (43.75) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Fang, M; Guo, X; Jiang, F; Lin, N; Ma, N; Ma, Z; Mao, X; Wang, J; Wang, Q; Yin, X; Yu, L; Zhang, Y | 1 |
| He, R; Huang, J; Liu, S; Pan, X; Shao, Y; Shi, T; Xi, J; Yu, W; Zhuang, R | 1 |
| Guo, Z; Hua, H; Jiang, Y; Liu, Y; Wang, J; Zhang, H; Zhang, J | 1 |
| Dong, H; Jing, W; Jun, X; Min, M; Runpeng, Z; Shuo, L; Yingru, X | 1 |
| Gao, JJ; Wang, K; Yao, X; Yin, H; Zhao, CR | 1 |
| Chen, BC; Chen, XQ; Jiang, N; Li, RT; Mao, ZW; Peng, W; Ye, RR | 1 |
| Chen, PH; Dai, HQ; Deng, JH; Feng, J; Huang, XW; Li, ZJ; Liu, YJ; Lu, GD; Shi, H; Wang, JG; Wang, ZX; Wu, Y; Yang, XM; Zhou, J | 1 |
| He, R; Huang, J; Ju, L; Liu, S; Pan, X; Xi, J; Zhao, Y; Zhuang, R | 1 |
| Chen, JQ; Guo, XL; Liu, JQ; Lv, XT; Qian, P; Sun, LQ; Yue, SY; Zhang, YW; Zhou, ZH | 1 |
| Baoxian, T; Dong, H; Jinbo, Y; Jing, W; Min, M; Rongbo, Z; Ru, C; Runpeng, Z; Shengfa, N; Weidong, H; Xuewei, X; Yingru, X | 1 |
| Ren, T; Wang, F; Wang, X; Yang, Y; Yu, B; Zhang, X; Zhao, X | 1 |
| Bogaerts, E; Colle, I; Descamps, B; Devisscher, L; Geerts, A; Janssens, S; Lambrecht, BN; Laukens, D; Libbrecht, L; Paridaens, A; Van Steenkiste, C; Van Vlierberghe, H; Vandewynckel, YP; Vanhove, C; Verhelst, X | 1 |
| Ilamathi, M; Santhosh, S; Sivaramakrishnan, V | 1 |
| Hou, J; Wang, D; Wang, H; Zhang, R | 1 |
| Li, AY; Wang, NP; Wang, Q; Wu, LM; Zhao, Y | 1 |
| Baur, A; Berger, TG; Dieckmann, D; Efferth, T; Funk, JO; Schuler, G; Schultz, ES | 1 |
16 other study(ies) available for artesunic acid and Cancer of Liver
| Article | Year |
|---|---|
Preclinical investigation of artesunate as a therapeutic agent for hepatocellular carcinoma via impairment of glucosylceramidase-mediated autophagic degradation.
Topics: Animals; Artesunate; Autophagy; Carcinoma, Hepatocellular; Glucosylceramidase; Glutathione; Humans; Liver Neoplasms; Mice; Rats; Sequestosome-1 Protein; Transferases | 2022 |
pH-Responsive and liver-targeting drug delivery system for combination delivery of artesunate with arsenic trioxide prodrug against hepatocellular carcinoma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Artesunate; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Delivery Systems; Humans; Hydrogen-Ion Concentration; Liposomes; Liver Neoplasms; Polyethylene Glycols; Prodrugs | 2023 |
Targeting HSP70 chaperones by rhein sensitizes liver cancer to artemisinin derivatives.
Topics: Artemisinins; Artesunate; Endoplasmic Reticulum Chaperone BiP; HSC70 Heat-Shock Proteins; HSP70 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; Humans; Liver Neoplasms; Luciferases; Molecular Chaperones | 2024 |
Artesunate promotes sensitivity to sorafenib in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Artesunate; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Liver Neoplasms; MAP Kinase Signaling System; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-akt; Sorafenib; TOR Serine-Threonine Kinases | 2019 |
Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Artesunate; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mice, Inbred BALB C; Mice, Nude; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Mitochondria-targeted artesunate conjugated cyclometalated iridium(iii) complexes as potent anti-HepG2 hepatocellular carcinoma agents.
Topics: Antineoplastic Agents; Apoptosis; Artesunate; Carcinoma, Hepatocellular; Coordination Complexes; Hep G2 Cells; Humans; Iridium; Liver Neoplasms | 2020 |
Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Artesunate; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Ferroptosis; Humans; Lipid Peroxidation; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxidative Stress; Sorafenib; Xenograft Model Antitumor Assays | 2021 |
Preparation, evaluation, and
Topics: Artesunate; Carcinoma, Hepatocellular; Drug Carriers; Glycyrrhetinic Acid; Humans; Liver Neoplasms; Nanoparticles; Particle Size; Polyesters; Polyethylene Glycols | 2020 |
Artesunate enhances γδ T-cell-mediated antitumor activity through augmenting γδ T-cell function and reversing immune escape of HepG2 cells.
Topics: Artemisinins; Artesunate; Carcinoma, Hepatocellular; Hep G2 Cells; Humans; Immunity, Cellular; Liver Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Tumor Escape | 2018 |
Dependence of artesunate on long noncoding RNA-RP11 to inhibit epithelial-mesenchymal transition of hepatocellular carcinoma.
Topics: Artesunate; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Neoplasm Invasiveness; RNA, Long Noncoding | 2019 |
Enhanced delivery of artemisinin and its analogues to cancer cells by their adducts with human serum transferrin.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Artemisinins; Artesunate; Carcinoma, Hepatocellular; Cell Proliferation; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Carriers; Drug Stability; Hep G2 Cells; Humans; Lactones; Liver Neoplasms; Lung Neoplasms; Molecular Docking Simulation; Molecular Structure; Nanotechnology; Protein Conformation; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Technology, Pharmaceutical; Transferrin | 2014 |
Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent.
Topics: Animals; Antineoplastic Agents; Artemisinins; Artesunate; Carcinoma, Hepatocellular; Cell Death; Dose-Response Relationship, Drug; Drug Repositioning; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Unfolded Protein Response | 2014 |
Artesunate as an Anti-Cancer Agent Targets Stat-3 and Favorably Suppresses Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Artemisinins; Artesunate; Carcinoma, Hepatocellular; Cell Line, Tumor; Dimerization; Humans; Liver Neoplasms; Molecular Docking Simulation; STAT3 Transcription Factor | 2016 |
Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action.
Topics: Animals; Antineoplastic Agents; Artemether; Artemisinins; Artesunate; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Liver; Liver Neoplasms; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2008 |
[Experimental studies of antitumor effect of artesunate on liver cancer].
Topics: Animals; Antineoplastic Agents, Phytogenic; Artemisia annua; Artemisinins; Artesunate; Carcinoma, Hepatocellular; Female; Humans; Inhibitory Concentration 50; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Neoplasm Transplantation; Phytotherapy; Sesquiterpenes; Tumor Cells, Cultured | 2001 |
Artesunate in the treatment of metastatic uveal melanoma--first experiences.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Artemisia; Artemisinins; Artesunate; Dacarbazine; Fatal Outcome; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Melanoma; Sesquiterpenes; Time Factors; Treatment Outcome; Uveal Neoplasms | 2005 |